Metabolomics Services Market Outlook 2031
The global metabolomics services market size was valued at USD 484.5 million in 2022 and is likely to reach USD 1511.6 million by 2031, expanding at a CAGR of 14.4% during 2023 – 2031. The growth of the market is attributed to the increasing utilization of metabolomics services to assess the effectiveness and safety of new drugs.
Increasing occurrence of cancer is resulting in a high demand for early detection and diagnosis services, which significantly boosts the metabolomics services market. Metabolomics services identify specific metabolic markers associated with different types of cancer, enabling healthcare professionals to diagnose the disease.
Additionally, early detection capabilities of metabolomics services further improve the chances of successful treatment and help to reduce cancer-related deaths.
-
According to the report published by WHO on February 3, 2022, cancer is the primary cause of death across the globe. About 10 million deaths were caused by cancer in 2020, which is almost one in six deaths. The most common types of cancer include lung cancer, colon and rectal cancer, breast cancer, and prostate.
Metabolomics services involve the analysis of small molecules, or metabolites in biological samples, such as blood, urine, or tissues. These services use advanced analytical techniques to identify and quantify a wide range of metabolites, which help researchers, healthcare professionals, and various industries to understand an individual's metabolic status.
The report found that the COVID-19 pandemic hampered the market. The pandemic disrupted laboratory operations across the globe. Lockdowns, social distancing measures, and supply chain interruptions led to delays and created challenges in conducting metabolomics research.
Many research facilities had to adapt to remote work, affecting the efficiency and capacity of these services. These logistical difficulties temporarily halted some metabolomics projects.
Artificial Intelligence (AI) Impact on Metabolomics Services Market
The emergence of artificial intelligence is expected to propel the market. AI enables the rapid processing and interpretation of vast amounts of metabolomics data, leading to a deep understanding of complex metabolic patterns.
Additionally, AI-driven algorithms identify subtle metabolic changes associated with various diseases, aiding in early diagnosis and personalized treatment strategies
Metabolomics Services Market Dynamics
Major Drivers
Growing utilization of metabolomics in drug development is expected to drive the market. Metabolomics services are improving drug development by helping assess the efficiency and safety of the new medication.
It provides insights into how drugs interact with metabolic pathways and helps identify potential biomarkers for drug responses. Furthermore, the increasing number of clinical studies is propelling the demand for accurate and reliable metabolomics services.
-
According to the report published on May 31, 2023, an estimated 454,000 clinical studies were registered worldwide, an increase of 16,270 as compared to 2022.
Existing Restraints
High cost of metabolomics services is expected to hinder the market. Metabolomics research and services are expensive, due to the high costs associated with instrumentation, data analysis, and skilled personnel.
This cost factor limits the accessibility of these services to small research institutions or resource-constrained organizations. Furthermore, the complexity of analyzing and extracting meaningful insights from this metabolomics data further reduces their demand.
Emerging Opportunities
Continuous ongoing research and advancements in metabolomics instruments and tools are expected to create immense opportunities for the players competing in the market. Manufacturers are focusing on upgrading instrumentation in mass spectrometry and NMR spectroscopy.
These developments improve sensitivity and accuracy in detecting and quantifying metabolites by tracing tiny amounts of small molecules with high precision. Metabolomics is heavily used in healthcare and pharmaceuticals for diagnostic and therapeutic implications, thereby fueling the market.
Scope of the Metabolomics Services Market Report
The report on the market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Metabolomics Services Market- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Type (Untargeted Metabolomics Services and Targeted Metabolomics Services), Products and Services (Metabolomics Bioinformatics Services, Chromatography, Mass Spectrometry, and Others), End-user (Agriculture & Food, Biomedical & Pharmaceutical, Academic & Research Labs, Diagnostic Laboratories, and Others)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Afekta Technologies Ltd; Agilent Technologies Inc; Analytik Jena GmbH+Co. KG; BASF SE; BGI; biocrates life sciences ag; Creative Proteomics; DH Tech. Dev. Pte. Ltd; DNA Xperts Private Limited; Drucker Diagnostics; Human Metabolome Technologies America Inc; LECO Corporation; Lifespin GmbH; Metabolomic Technologies Inc; Metabolon Inc; Metware Biotechnology Co.Ltd; MS-OMICS; PerkinElmer Inc; Shimadzu Corporation; Thermo Fisher Scientific Inc; and Waters Corporation
|
Metabolomics Services Market Segment Insights
Type Analysis
Based on type, the metabolomics services market is bifurcated into untargeted metabolomics services and targeted metabolomics services. The untargeted metabolomics services segment is expected to hold a major market share during the forecast period, due to its wide-reaching ability and comprehensive analysis of all metabolites present in a sample. This approach does not focus on specific compounds and provides a detailed view of the metabolic landscape.
Researchers and clinicians use this depth of information to uncover unexpected associations and biomarkers that targeted approaches miss. Furthermore, the versatility of these metabolomics services to various applications further boosts their demand.
Products and Services Analysis
On the basis of products and services, the market is classified as metabolomics bioinformatics services, chromatography, mass spectrometry, and others. The mass spectrometry segment is anticipated to register robust growth in the coming years, owing to its exceptional precision and sensitivity in detecting and quantifying metabolites in biological samples.
It identifies a wide range of molecules, making it a versatile tool for metabolomics. Moreover, major key players are continuously developing and introducing new mass spectrometry products, which further boosts the market growth.
-
On June 06, 2022, Waters Corporation, a global manufacturer and distributor of analytical instruments, announced the launch of their new mass spectrometer Xevo G3 quadrupole time-of-flight (QTof). This new technology is suitable for quantifying and characterizing thermally fragile molecules, including metabolite identification, metabolomics, biotherapeutics, forensics, and extractable and leachable. Additionally, this mass spectrometry is 10X more sensitive than its class-leading predecessor.
End-user Analysis
In terms of end-user, the metabolomics services market is fragmented into agriculture & food, biomedical & pharmaceutical, academic & research labs, diagnostic laboratories, and others. The biomedical & pharmaceuticals segment is expected to hold a key market share during the projection period, due to the high utilization of metabolomics services in drug development and discovery.
Metabolomics aids in comprehending how drugs affect metabolic pathways and identifies potential biomarkers. This critical information streamlines the drug development process and enhances the efficiency of new pharmaceutical compounds.
The academic and research labs segment is projected to register a considerable CAGR during the forecast period, as researchers are utilizing metabolomics services to discover novel biomarkers for various diseases and conditions. These biomarkers have the ability to help in early diagnosis, treatment monitoring, and the development of precision medicine therapies.
Moreover, increasing research in genomics and proteomics, to gain a comprehensive understanding of complex biological systems propels the demand for accurate metabolomics services in the market.
Regional Outlook
In terms of region, the global metabolomics services market is segmented into Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market, due to the well-established healthcare regulations that ensure the quality and safety of medical services, including metabolomics.
This regulatory framework fosters trust in the services provided, attracting both patients and researchers. Moreover, the robust pharmaceutical industry in the region relies on metabolomics for drug development and safety assessment. These all factors contribute to the market growth in this region.
The market in Asia Pacific is anticipated to expand at a rapid pace in the coming years, due to the vast and diverse population. Metabolomics services are important in addressing the diverse healthcare needs and genetic variations.
Furthermore, the rising burden of diseases such as diabetes, cardiovascular conditions, and cancers contributes to the growing demand for metabolomics services.
- According to a report published by the National Library of Medicine on January 30, 2022, the rate of cancer incidence in Asia Pacific was 169.1 per 100000 in 2020, accounting for 49.3% of global cancer incidence.
Segments
The global metabolomics services market has been segmented on the basis of
Type
- Untargeted Metabolomics Services
- Targeted Metabolomics Services
Product and Services
- Metabolomics Bioinformatics Services
- Chromatography
- Mass Spectrometry
- Others
End-user
- Agriculture & Food
- Biomedical & Pharmaceutical
- Academic & Research Labs
- Diagnostic Laboratories
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Afekta Technologies Ltd
- Agilent Technologies Inc
- Analytik Jena GmbH+Co. KG
- BASF SE
- BGI
- biocrates life sciences ag
- Creative Proteomics
- DH Tech. Dev. Pte. Ltd
- DNA Xperts Private Limited
- Drucker Diagnostics
- Human Metabolome Technologies America Inc
- LECO Corporation
- Lifespin GmbH
- Metabolomic Technologies Inc
- Metabolon Inc
- Metware Biotechnology Co.Ltd
- MS-OMICS
- PerkinElmer Inc
- Shimadzu Corporation
- Thermo Fisher Scientific Inc
- Waters Corporation
Competitive Landscape
Key players competing in the global metabolomics services market are Afekta Technologies Ltd; Agilent Technologies Inc; Analytik Jena GmbH+Co. KG; BASF SE; BGI; biocrates life sciences ag; Creative Proteomics; DH Tech. Dev. Pte. Ltd; DNA Xperts Private Limited; Drucker Diagnostics; Human Metabolome Technologies America Inc; LECO Corporation; Lifespin GmbH; Metabolomic Technologies Inc; Metabolon Inc; Metware Biotechnology Co.Ltd; MS-OMICS; PerkinElmer Inc; Shimadzu Corporation; Thermo Fisher Scientific Inc; and Waters Corporation
These companies are focusing on various strategies, such as partnerships, mergers, reduction in production costs, launching new products, and implementing advanced technologies to expand their market share.
- On March 29, 2023, Lifespin GmbH, a prominent medical technology company, announced their granted certification for ISO13485 to its Regensburg-based AI-based metabolomics technology platform. This certification helps the company towards its first commercial product launch at the end of the year.
Request For Customization
Enquiry Before Buying
Speak With Analyst
